Accéder au contenu
Merck
Toutes les photos(1)

Principaux documents

L5545

Sigma-Aldrich

Levosimendan

≥98% (HPLC)

Synonyme(s) :

(-)-OR-1259, (R)-Simendan, 2-[2-[4-[(4R)-1,4,5,6-Tetrahydro-4-methyl-6-oxo-3-pyridazinyl]phenyl]hydrazinylidene]-propanedinitrile, OR 1259, R)-((4-(1,4,5,6-Tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl)hydrazono) propanedintrile

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme


About This Item

Formule empirique (notation de Hill):
C14H12N6O
Numéro CAS:
Poids moléculaire :
280.28
Numéro MDL:
Code UNSPSC :
12352202
ID de substance PubChem :
Nomenclature NACRES :
NA.77

Le tarif et la disponibilité ne sont pas disponibles actuellement.

Niveau de qualité

Essai

≥98% (HPLC)

Forme

powder

Activité optique

[α]/D -500 to -650°, c = 0.5 in THF

Couleur

yellow

Solubilité

DMSO: ≥20 mg/mL

Température de stockage

room temp

Chaîne SMILES 

C[C@@H]1CC(=O)NN=C1c2ccc(N\N=C(\C#N)C#N)cc2

InChI

1S/C14H12N6O/c1-9-6-13(21)19-20-14(9)10-2-4-11(5-3-10)17-18-12(7-15)8-16/h2-5,9,17H,6H2,1H3,(H,19,21)/t9-/m1/s1

Clé InChI

WHXMKTBCFHIYNQ-SECBINFHSA-N

Comparer avec des articles similaires

Voir la comparaison complète

Montrer les différences

1 of 4

Cet article
135663213565521356563
grade

pharmaceutical primary standard

grade

pharmaceutical primary standard

grade

pharmaceutical primary standard

grade

pharmaceutical primary standard

application(s)

pharmaceutical (small molecule)

application(s)

pharmaceutical (small molecule)

application(s)

pharmaceutical (small molecule)

application(s)

pharmaceutical (small molecule)

format

neat

format

neat

format

neat

format

neat

API family

ketoprofen

API family

ketoprofen

API family

ketoprofen

API family

ketoprofen

Application

Levosimendan has been used for screening its anti-human immunodeficiency virus type 1 (HIV-1) property.[1] It has also been used for screening its cytotoxic effects in TP53 mutant and wild-type lung adenocarcinoma cell lines[2]

Actions biochimiques/physiologiques

Levosimendan has a potential to inhibit both acute human immunodeficiency virus type 1 (HIV-1) replication and the reactivation of latent HIV-1 proviruses. Therefore, it is considered to be a promising anti-HIV-1 agent.[1]
Levosimendan is a calcium sensitiser.
Levosimendan is a calcium sensitiser. The compound increases the sensitivity of the heart to calcium, thus increasing cardiac contractility without a rise in intracellular calcium. Levosimendan binds to cardiac troponin C in a calcium-dependent manner and stabilizes troponin C. This is followed by actin-myosin cross-bridges, without increasing myocardial consumption of ATP. Additionally the compound acts as vasodilator by opening an ATP-sensitive potassium channels. Levosimendan is a drug used for treatment of congestive heart failure. Also it can be used to treat calcium channel blocker overdose.

Pictogrammes

Exclamation mark

Mention d'avertissement

Warning

Mentions de danger

Classification des risques

Acute Tox. 4 Dermal - Acute Tox. 4 Inhalation - Acute Tox. 4 Oral

Code de la classe de stockage

11 - Combustible Solids

Classe de danger pour l'eau (WGK)

WGK 3

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable


  • Faites votre choix parmi les versions les plus récentes :

    Certificats d'analyse (COA)

    Lot/Batch Number

    Vous ne trouvez pas la bonne version ?

    Si vous avez besoin d'une version particulière, vous pouvez rechercher un certificat spécifique par le numéro de lot.

    Déjà en possession de ce produit ?

    Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

    Consulter la Bibliothèque de documents

    Les clients ont également consulté

    Annina Jacky et al.
    Journal of cardiothoracic and vascular anesthesia, 32(5), 2112-2119 (2018-05-12)
    Pharmacodynamics suggests that levosimendan might be a valuable inotrope for weaning from extracorporeal life support (ECLS). As there is a paucity of evidence regarding the effectiveness and safety of such an approach, the aim was to report the authors' experiences
    Julia Hasslacher et al.
    Critical care (London, England), 15(4), R166-R166 (2011-07-14)
    Levosimendan is an extensively investigated inodilator showing also cardioprotective and antiinflammatory effects. The aim of our study was to explore the influence of levosimendan on polymorphonuclear leucocytes (PMN), a main source of reactive oxygen species, in vitro and in patients
    Peter Onody et al.
    PloS one, 8(9), e73758-e73758 (2013-09-17)
    Temporary occlusion of the hepatoduodenal ligament leads to an ischemic-reperfusion (IR) injury in the liver. Levosimendan is a new positive inotropic drug, which induces preconditioning-like adaptive mechanisms due to opening of mitochondrial KATP channels. The aim of this study was
    A Candidate Cell-Selective Anticancer Agent
    Probe Reports from the NIH Molecular Libraries Program, 146, 76-85 (2014)
    Pertti K Suominen
    BMC anesthesiology, 11, 18-18 (2011-10-07)
    Levosimendan has pharmacologic and hemodynamic advantages over conventional intravenous inotropic agents. It has been used mainly as a rescue drug in the pediatric intensive care unit or in the operating room. We present the largest single-center experience of levosimendan in

    Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

    Contacter notre Service technique